Literature DB >> 19768488

Pacemaker upgrade causing new-onset heart failure in a patient with complete congenital atrioventricular block.

Charles T Nguyen1, Carlos E Moreno-Cabral, C Becket Mahnke.   

Abstract

For infants with congenital complete atrioventricular block (CCAVB), the choice of pacing modalities is limited. Due to their size and surgical limitations, neonates typically start with an epicardial right ventricular pacing system, then upgrade to right-sided dual-chamber pacing once appropriate size is achieved. These modes are generally well tolerated. However, the reported case involved a patient with CCAVB who paradoxically experienced congestive heart failure after upgrading to a dual-chamber system, a theoretically superior pacing modality. With conversion to biventricular pacing, a relatively new modality for adults with very little pediatric experience to date, the patient's symptoms dramatically improved.

Entities:  

Mesh:

Year:  2009        PMID: 19768488     DOI: 10.1007/s00246-009-9525-z

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  3 in total

1.  Images in cardiovascular medicine. Cardiac resynchronization by restoration of native ventricular activation: reversal of iatrogenic mitral regurgitation and heart failure.

Authors:  Sandeep Sagar; Arshad Jahangir; Raul E Espinosa; Curtis R Louwagie; Lyle J Olson
Journal:  Circulation       Date:  2008-04-22       Impact factor: 29.690

2.  Dilated cardiomyopathy following right ventricular pacing for AV block in young patients: resolution after upgrading to biventricular pacing systems.

Authors:  Jeffrey P Moak; Keren Hasbani; Carolyn Ramwell; Vicki Freedenberg; John T Berger; Gregory DiRusso; Patrick Callahan
Journal:  J Cardiovasc Electrophysiol       Date:  2006-10

Review 3.  Physiology of cardiac pacing in children: the importance of the ventricular pacing site.

Authors:  Ward Y Vanagt; Frits W Prinzen; Tammo Delhaas
Journal:  Pacing Clin Electrophysiol       Date:  2008-02       Impact factor: 1.976

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.